Evidence map›Paper›PMID 21895995›Full record

ReviewMicrobial biotechnology2012

Hydrogen production by recombinant Escherichia coli strains.

Toshinari Maeda, Viviana Sanchez-Torres, Thomas K Wood

Abstract readReview
In one paragraph

Review in Microbial biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Mini-review:Computational and structural biotechnology journal · 2017
    Review
  12. Review
  13. Article
  14. Article
  15. High-yield hydrogen production from biomass by in vitro metabolic engineering: Mixed sugars coutilization and kinetic modeling.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Toshinari MaedaDepartment of Chemical Engineering, Texas A & M University, 220 Jack E. Brown Building, College Station, TX 77843-3122, USA. toshi.maeda@life.kyutech.ac.jp
Viviana Sanchez-Torres
Thomas K Wood

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The production of hydrogen via microbial biotechnology is an active field of research. Given its ease of manipulation, the best-studied bacterium Escherichia coli has become a workhorse for enhanced hydrogen production through metabolic engineering, heterologous gene expression, adaptive evolution, and protein engineering. Herein, the utility of E. coli strains to produce hydrogen, via native hydrogenases or heterologous ones, is reviewed. In addition, potential strategies for increasing hydrogen production are outlined and whole-cell systems and cell-free systems are compared.

Indexed as

Metabolic EngineeringMetabolic Networks and PathwaysBiotechnologyEscherichia coliHydrogenHydrogenaseRecombinant ProteinsHydrogenHydrogenaseRecombinant Proteins

Identifiers

PMID21895995
PMCPMC3815781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.